This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine)Broad pneumococcal defenseMOABurden of diseaseIPDCAPPatient profilesPatient profilesRoger, 59: DiabetesSean, 35: AsthmaWilliam, 55: COPDJanet, 58: Chronic Heart DiseaseSophia, 71: Healthy ≥65; Previously VaccinatedMary, 65: Healthy ≥65; Unknown Vaccination HistoryACIP recommendationsACIP recommendationsACIP recommendationsClinical studies

Clinical studies

Built on PCV13Study 1 resultsStudy 1 designStudy 1 safetyStudy 6 resultsStudy 6 designStudy 6 safetyCAPiTAAdministrationAccess & supportAccess & supportMedicareCommercial health plansEventsMaterialsVideos
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
Certain underlying medical conditions can increase the risk of acquiring or dying from IPD1
Certain underlying medical conditions can increase the risk of acquiring or dying from IPD1
 ReferencesBased on a multicenter, observational cohort study conducted at 20 ICUs in France. Vaccination status and serotype information were not collected.2 ReferencesThe mortality rate includes patients of all ages, including children.Chronic medical conditions include: alcoholism; chronic heart, liver, or lung disease; cigarette smoking; or diabetes.6

Vaccine serotypes associated with IPD cases

Percentage of potential IPD cases covered by vaccine serotypes7§||¶


Prevnar 20 contains serotypes that account for the majority of cases of IPD in adults in the US7,8

There are currently no studies comparing the efficacy of Prevnar 20 to a 15-valent pneumococcal conjugate vaccine.

Vaccine serotypes associated with IPD cases

Percentage of potential IPD cases covered by vaccine serotypes7§||¶

Prevnar 20 contains serotypes that account for the majority of cases of IPD in adults in the US7,8

There are currently no studies comparing the efficacy of Prevnar 20 to a 15-valent pneumococcal conjugate vaccine.

CAP=community-acquired pneumonia; CHF=congestive heart failure; CMC=chronic medical conditions; COPD=chronic obstructive pulmonary disease; CSF=cerebrospinal fluid; HIV=human immunodeficiency virus; IC=immunocompromising conditions; ICU=intensive care unit; IPD=invasive pneumococcal disease; MOA=mechanism of action.13 serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 6C (highly related to 6A). 15 serotypes include all 13 serotypes and the additional serotypes 22F and 33F. 20 serotypes include all 15 serotypes and the additional serotypes 8, 10A, 11A, 12F, and 15B.7Percentages for adults age 19 to 64 with chronic medical conditions and 19 to 64 with immunocompromising conditions based on Active Bacterial Core surveillance data collected by the Centers for Disease Control and Prevention from 2017 through 2018.7Percentages for adults age 65 or older based on Active Bacterial Core surveillance data collected by the Centers for Disease Control and Prevention from 2018 through 2019.7Alcoholism; chronic heart disease (including CHF and cardiomyopathies); chronic liver disease; chronic lung disease (including COPD, emphysema, and asthma); chronic renal failure††; cigarette smoking; cochlear implant; congenital or acquired asplenia††; cerebrospinal fluid leak; diabetes; generalized malignancy††; HIV infection††; Hodgkin disease††; congenital or acquired immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency, complement deficiencies [particularly C1, C2, C3, and C4 deficiencies], and phagocytic disorders [excluding chronic granulomatous disease])††; iatrogenic immunosuppression (diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy)††; leukemia††; lymphoma††; multiple myeloma††; nephrotic syndrome††; solid organ transplant††; sickle cell disease or other hemoglobinopathies.††9Immunocompromising conditions.References:Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70:984-989.Garrouste-Orgeas M, Azoulay E, Ruckly S, et al. Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: A multicenter observational study from the Outcomerea Research Group. Infection. 2018;46:669-677.Data on file. Pfizer, Inc.Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831-1838.Gierke R, Wodi, P Kobayashi M. Pneumococcal disease. Updated August 18, 2021. Accessed June 13, 2023. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.htmlKobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-117.Kobayashi M. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. Presented at: Advisory Committee on Immunization Practices; October 20, 2021. Accessed June 13, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/02-Pneumococcal-Kobayashi-508.pdfPrevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. Updated March 15, 2023. Accessed June 12, 2023. https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdfPrevnar 20®
See what the CDC recommends for pneumococcal vaccination
View the guidelines
Loading
Meet patient types eligible for Prevnar 20
 Patient profiles Loading
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Manufactured by Wyeth Pharmaceuticals LLC.
© 2023 Pfizer Inc.

All rights reserved.

Marketed by Pfizer Inc.
July 2023

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2023 Pfizer Inc. All rights reserved.

PP-PNR-USA-1404
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

​​​​​​​
INDICATIONS AND SELECT SAFETY INFORMATION
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

SELECT SAFETY INFORMATION
 
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
Important Safety Information
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • For Prevnar 20®, in individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age  
  • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.

Please click for Prevnar 13® Full Prescribing Information.Indications
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older 
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine